Who is sponsoring NCT03996512?

NCT03996512 is sponsored by University of Florida.

What drugs are being tested in NCT03996512?

Interventions in NCT03996512: Early Active Controlled Motion (EACM).

What condition does NCT03996512 study?

NCT03996512 studies Scaphoid Fixation.

Is NCT03996512 still recruiting?

NCT03996512 is currently withdrawn. Last updated 25 June 2021.

Last reviewed 2021-06-25 · How we verify

NCT03996512

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Early Active Controlled Motion (EACM) Rehabilitation Protocol Post Open Reduction and Internal Fixation (ORIF) of Scaphoid Fractures: A Pilot Study

Withdrawn NA Last updated 25 June 2021

What this trial tests

NA trial testing Early Active Controlled Motion (EACM) in Scaphoid Fixation. Withdrawn.

Timeline

1 August 2019

Primary endpoint
19 January 2021

19 January 2021

Quick facts

Lead sponsor	University of Florida
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	1 August 2019
Primary completion	19 January 2021
Estimated completion	19 January 2021

Drugs / interventions tested

Early Active Controlled Motion (EACM)

Conditions studied

Scaphoid Fixation — all drugs for Scaphoid Fixation →

Sponsor

University of Florida

Who can join

Adults 18 to 100, any sex, with Scaphoid Fixation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There is poor research supporting the benefits of Early Active Controlled Motion (EACM) protocols post operative scaphoid fixation. Advances in surgical fixation technique for scaphoid fractures should allow for start of earlier mobilization, however there is little evidence in the literature that supports the use of these protocols within the early phases of healing. The study uses a pre-experimental design with purposeful sample population recruitment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University of Florida trials

Trials by the same sponsor.

NCT03429413 — Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial · NA · not yet recruiting
NCT06127550 — taVNS for Letter Learning in Dyslexia · NA · suspended
NCT07507214 — Optimized, Neuroplasticity-Enhanced-Depression (ONE-D) Transcranial Magnetic Stimulation (TMS) Treatment for Female Athl · Phase 2, PHASE3 · not yet recruiting
NCT07492316 — RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB) · Phase 1 · not yet recruiting
NCT06670794 — Using Ecological Momentary Data to Inform a Web Intervention for Romantic Partners Concerned About Their Loved Ones' Dri · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03996512 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Florida
Last refreshed: 25 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03996512.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing